Immediate Action Required: Modify Your Testosterone Regimen
You should reduce your testosterone dose or switch to a different formulation immediately due to your elevated hematocrit of 52%, and you need urgent urological evaluation for your PSA of 6.09 ng/mL before continuing any testosterone therapy. 1, 2
Critical Safety Concerns
Hematocrit at 52%
Your hematocrit is approaching the critical threshold of 54% where testosterone therapy must be stopped. The 2018 Endocrine Society guidelines explicitly state that therapy should be stopped if hematocrit exceeds 54% until it decreases to a safe level 2. Your current level of 52% puts you dangerously close to this cutoff.
Immediate management options:
- Reduce your dose from 200 mg every 2 weeks to 100 mg weekly - This regimen significantly reduces the risk of hematocrit rising above 54% (1% vs 8% risk) while maintaining therapeutic testosterone levels 3
- Consider switching to intranasal testosterone gel, which does not significantly affect hematocrit levels unlike intramuscular injections 4
- The 200 mg biweekly regimen you're currently using creates higher average serum testosterone over the dosing interval, which is directly associated with increased erythrocytosis risk 3
PSA at 6.09 ng/mL - Requires Urgent Evaluation
Your PSA of 6.09 ng/mL mandates immediate urological consultation before continuing testosterone therapy. The Endocrine Society guidelines specify that urological consultation is required for:
- Confirmed PSA >4 ng/mL at any time
- PSA increase >1.4 ng/mL within 12 months of starting treatment 2
Your PSA exceeds both thresholds. While the 2025 TRAVERSE trial showed no increased prostate cancer incidence with testosterone therapy 1, and PSA elevations are common (mean increase from 1.86 to 2.82 ng/mL) 5, a PSA of 6.09 is above the threshold requiring prostate biopsy consideration 2.
Recommended Treatment Algorithm
Step 1: Stop current 200 mg biweekly injections immediately
Step 2: Obtain urgent urology consultation for:
- Digital rectal examination
- Possible prostate biopsy given PSA >4 ng/mL
- Rule out prostate cancer before resuming therapy
Step 3: If prostate evaluation is negative:
- Switch to 100 mg testosterone cypionate weekly (reduces erythrocytosis risk by 87% compared to your current regimen) 3
- Alternative: Consider intranasal testosterone gel 11 mg three times daily (no significant hematocrit increase) 4
Step 4: Monitor closely:
- Recheck hematocrit in 3 months (target <50%)
- Recheck PSA in 3 months
- If hematocrit continues rising toward 54%, consider complete dose reduction to 100 mg every 2 weeks 6 or therapeutic phlebotomy 2
Key Clinical Pitfalls
The 200 mg biweekly regimen creates supraphysiologic testosterone peaks that drive erythrocytosis more aggressively than more frequent, lower-dose injections 3. Many clinicians fail to recognize that dose fractionation (100 mg weekly) maintains therapeutic testosterone levels while dramatically reducing hematocrit elevation 3, 6.
Your PSA elevation may represent normal testosterone-induced increases, but any PSA >4 ng/mL requires investigation regardless of testosterone therapy 2. Do not continue therapy until prostate cancer is excluded.
Monitoring After Regimen Change
Once cleared by urology and switched to lower-dose regimen: